Use Of Cytoplasmic C-Myc For Regulating Immune Responses
The Subject Invention Provides Novel Uses Of Cytoplasmic C-Myc For Modulation Of Innate Immune Responses. The Invention Is Based, At Least In Part, On The Surprising Discovery That Cytoplasmic C-Myc, Instead Of Nuclear C-Myc, Modulates Pro-Inflammatory Immune Responses Via Its Role As A Positive Feedback Regulator. Specifically, The Subject Invention Provides Methods For Treatment Or Amelioration Of Inflammatory Diseases And/Or Immune Disorders Via Inhibition C-Myc Expression Or Its Activity. Also Provided Are Methods For The Development Of Therapeutic Agents For Treating Infection, Inflammation, Immune Diseases And Autoimmune Diseases.
Patent Number: US20120107317A1
Application Number: US13282084A
Inventor: LAU, ALLAN SIK YIN | Yim, Howard Chi Ho | Li, Chun Bong | Pong, John Chi Him
Priority Date: 27 Oct 2010
Priority Number: US20120107317A1
Application Date: 26 Oct 2011
Publication Date: 3 May 2012
IPC Current: A61K0039395 | A61K0031196 | A61K0031424 | A61K0031444 | A61K00315383 | A61K00317088 | A61K0031713 | A61K003817 | A61P000900 | A61P002900 | A61P003104 | A61P003110 | A61P003112 | A61P003118 | A61P003120 | A61P003122 | A61P003500 | A61P003704 | A61P003706 | A61P003708 | C12Q000168 | G01N0033566 | G01N0033573
US Class: 4241381 | 4242781 | 4350061 | 43500612 | 4350071 | 4350074 | 43500792 | 5140011 | 5140133 | 5140193 | 514044A | 5142295 | 514333 | 514375 | 514563
Assignee Applicant: The University of Hong Kong
Title: USE OF CYTOPLASMIC C-MYC FOR REGULATING IMMUNE RESPONSES
Usefulness: USE OF CYTOPLASMIC C-MYC FOR REGULATING IMMUNE RESPONSES
Summary: The method is useful for treating: infection, inflammation, allergenic reaction, neoangiogenesis, cardiovascular disease, and/or an autoimmune disease; inflammation associated with viral, bacterial, fungal, or protozoan infection, preferably mycobacteria infection; HIV infection, opportunistic infection concurrent with HIV infection, or AIDS-associated disorders; and cancer. The method is useful to concurrent infection by mycobacteria, Candida , Staphylococcus aureus , Salmonella , Escherichia coli , Listeria monocytogenes , Listeria amazonensis , herpes simplex virus (HSV), human papillomavirus (HPV), Kaposi's sarcoma-associated herpesvirus (KSHV), or hepatitis virus (all claimed). The method is useful for treating e.g.: rheumatoid arthritis, ulcerative colitis, Behcet's diseases, Crohn's disease, chronic inflammatory bowel diseases, graft-versus-host and transplant rejection, and related disorders of the joints or musculoskeletal system in which suppression of unwanted immune reaction and/or inflammation is beneficial; asthma, rhinitis, chronic obstructive pulmonary disease (COPD), chronic urticaria, atopic dermatitis, paranasal sinus disease, migraine, pancreatitis, and atherosclerosis; pulmonary and respiratory diseases including sleep-disorder, obstructive sleep apnea (OSA), pneumonitis following prior infection, interstitial lung disease, idiopathic pulmonary fibrosis, and cystic fibrosis; angina, acute myocardial infarction, stroke, atherosclerosis, thrombosis, coronary angioplasty, aortic aneurysms, vascular inflammation, intimal hyperplasia, and hyperlipidemia-dependent aortic aneurysm; renal insufficiency induced by immunological reactions or chemicals (such as cyclosporine), migraine, cluster headache, ocular conditions such as uveitis, trauma or shock (such as burn, injury and endotoxemia), and allograft transplant rejection; liver cirrhosis, glandular diseases such as thyroiditis, and renal and urologic diseases including glomerulonephritis; and dermatitis and other dermal diseases. No biological data given.
Novelty: Treating inflammation and/or autoimmune diseases, comprises reducing cytoplasmic c-Myc protein level and/or inhibiting c-Myc activity in the cytoplasm in a subject in need of such treatment
诊断/治疗
其他疾病
香港
